<DOC>
	<DOCNO>NCT02611232</DOCNO>
	<brief_summary>The main objective trial study whether daily treatment liraglutide improve insulin secretion glucose metabolism , whether liraglutide treatment tolerable safe subject preclinical type 1 diabetes age 18-30 year .</brief_summary>
	<brief_title>Incretin-based Therapy Preclinical Type 1 Diabetes Adults</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1830 year age positive least 2 biochemical islet autoantibody normal glucose tolerance OGTT pregnant allergic liraglutide ingredient Victoza® Type 1 diabetes diabetic ketoacidosis previous treatment last three month antidiabetic medication impair liver kidney function dialysis severe heart failure severe stomach gut problem result gastroparesis , inflammatory bowel disease past current history pancreatitis serum calcitonin value normal ( &gt; 50 ng/l ≥3.4pmol/l ) presence chronic metabolic , hematologic malignant disease obesity BMI ≥30 pregnant female female childbearing potential use adequate contraceptive method . breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Type 1</keyword>
	<keyword>Diabetes , Insulin-Dependent</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Preclinical Type 1 Diabetes</keyword>
	<keyword>GLP-1 Analogue</keyword>
</DOC>